1.
Recommendations on the treatment of metastatic hormone-sensitive prostate cancer: Patient selection.
Actas Urol Esp (Engl Ed)
; 2024 May 11.
Artículo
en Inglés, Español
| MEDLINE
| ID: mdl-38740263
RESUMEN
The standard treatment for metastatic hormone-sensitive prostate cancer (mHSPC) is now a combination of androgen deprivation therapy plus an androgen receptor-targeted therapy (abiraterone, apalutamide, enzalutamide or darolutamide), with or without chemotherapy (docetaxel). The selection of suitable patients for each therapeutic approach has become a determining factor to ensure efficacy and minimize side effects. This article combines recent clinical evidence with the accumulated experience of experts in medical oncology, radiation oncology and urology, to provide a comprehensive view and therapeutic recommendations for mHSPC.